Timothy A Chan

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. doi request reprint Genomic dissection of Hurthle cell carcinoma reveals a unique class of thyroid malignancy
    Ian Ganly
    Memorial Sloan Kettering Cancer Center Human Oncology and Pathogenesis Program, 1275 York Avenue, New York, New York 10065, USA
    J Clin Endocrinol Metab 98:E962-72. 2013
  2. doi request reprint Epigenetic biomarkers
    Timothy A Chan
    Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
    Curr Top Microbiol Immunol 355:189-216. 2012
  3. pmc Protein tyrosine phosphatase receptor delta acts as a neuroblastoma tumor suppressor by destabilizing the aurora kinase A oncogene
    Maria Meehan
    Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin 2, Dublin, Ireland
    Mol Cancer 11:6. 2012
  4. doi request reprint IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma
    Daniel Gorovets
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Clin Cancer Res 18:2490-501. 2012
  5. pmc IDH mutation impairs histone demethylation and results in a block to cell differentiation
    Chao Lu
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Nature 483:474-8. 2012
  6. pmc Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma
    Kasthuri Kannan
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Oncotarget 3:1194-203. 2012
  7. pmc Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation
    Luc G T Morris
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Nat Genet 45:253-61. 2013
  8. doi request reprint Abbreviated course of radiation therapy with concurrent temozolomide for high-grade glioma in patients of advanced age or poor functional status
    Marsha Reyngold
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    J Neurooncol 110:369-74. 2012
  9. pmc IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
    Sevin Turcan
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Nature 483:479-83. 2012
  10. doi request reprint An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells
    Dan Rohle
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Science 340:626-30. 2013

Collaborators

Detail Information

Publications19

  1. doi request reprint Genomic dissection of Hurthle cell carcinoma reveals a unique class of thyroid malignancy
    Ian Ganly
    Memorial Sloan Kettering Cancer Center Human Oncology and Pathogenesis Program, 1275 York Avenue, New York, New York 10065, USA
    J Clin Endocrinol Metab 98:E962-72. 2013
    ..Hurthle cell cancer (HCC) is an understudied cancer with poor prognosis...
  2. doi request reprint Epigenetic biomarkers
    Timothy A Chan
    Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
    Curr Top Microbiol Immunol 355:189-216. 2012
    ..The recent application of global analysis strategies has further accelerated our understanding of the epigenome and promises to enhance the identification of epigenomic programs underlying cancer progression and treatment response...
  3. pmc Protein tyrosine phosphatase receptor delta acts as a neuroblastoma tumor suppressor by destabilizing the aurora kinase A oncogene
    Maria Meehan
    Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin 2, Dublin, Ireland
    Mol Cancer 11:6. 2012
    ..The molecular mechanism, however, by which PTPRD renders a tumor suppressor effect in neuroblastoma is unknown...
  4. doi request reprint IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma
    Daniel Gorovets
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Clin Cancer Res 18:2490-501. 2012
    ..Accordingly, we sought to identify and characterize clinically relevant molecular subclasses of lower grade diffuse astrocytic gliomas...
  5. pmc IDH mutation impairs histone demethylation and results in a block to cell differentiation
    Chao Lu
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Nature 483:474-8. 2012
    ..Together these data demonstrate that 2HG can inhibit histone demethylation and that inhibition of histone demethylation can be sufficient to block the differentiation of non-transformed cells...
  6. pmc Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma
    Kasthuri Kannan
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Oncotarget 3:1194-203. 2012
    ..In summary, our findings both identify ATRX mutation as a defining molecular determinant for a large subset of IDH-mutant gliomas and have direct implications on pathogenic mechanisms across the wide spectrum of LGGs...
  7. pmc Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation
    Luc G T Morris
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Nat Genet 45:253-61. 2013
    ..Loss of FAT1 function is a frequent event during oncogenesis. These findings address two outstanding issues in cancer biology: the basis of Wnt activation in non-colorectal tumors and the identity of a 4q35 tumor suppressor...
  8. doi request reprint Abbreviated course of radiation therapy with concurrent temozolomide for high-grade glioma in patients of advanced age or poor functional status
    Marsha Reyngold
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    J Neurooncol 110:369-74. 2012
    ..Grade 3-4 hematologic toxicity occurred in 11 patients. Abbreviated RT with concurrent TMZ provides a clinical benefit, is safe and tolerable in patients of advanced age or poor functional status...
  9. pmc IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
    Sevin Turcan
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Nature 483:479-83. 2012
    ....
  10. doi request reprint An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells
    Dan Rohle
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Science 340:626-30. 2013
    ..These data suggest that mIDH1 may promote glioma growth through mechanisms beyond its well-characterized epigenetic effects...
  11. pmc Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers
    Luc G T Morris
    Human Oncology and Pathogenesis Program, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Proc Natl Acad Sci U S A 108:19024-9. 2011
    ..These findings have important implications for our understanding of head and neck cancer tumorigenesis and for the use of targeted agents for this malignancy...
  12. pmc Genome sequencing identifies a basis for everolimus sensitivity
    Gopa Iyer
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Science 338:221. 2012
    ....
  13. pmc Breast cancer methylomes establish an epigenomic foundation for metastasis
    Fang Fang
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Sci Transl Med 3:75ra25. 2011
    ..These findings significantly enhance our understanding of breast cancer oncogenesis and aid the development of new prognostic biomarkers for this common malignancy...
  14. pmc Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma
    Antonio Omuro
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Neuro Oncol 15:242-50. 2013
    ..In this phase II trial, we investigated the efficacy of a metronomic temozolomide schedule in the treatment of recurrent malignant gliomas (MGs)...
  15. doi request reprint MRI perfusion in determining pseudoprogression in patients with glioblastoma
    Robert J Young
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Clin Imaging 37:41-9. 2013
    ..001), and higher PSR (P=.039) than progression. DSC MRI perfusion successfully identified pseudoprogression in patients who did not require a change in treatment despite radiographic worsening following chemoradiotherapy...
  16. pmc Comparative genomic analysis of primary versus metastatic colorectal carcinomas
    Efsevia Vakiani
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 30:2956-62. 2012
    ..To compare the mutational and copy number profiles of primary and metastatic colorectal carcinomas (CRCs) using both unpaired and paired samples derived from primary and metastatic disease sites...
  17. doi request reprint Biomarkers for detection and prognosis of breast cancer identified by a functional hypermethylome screen
    Jana Jeschke
    Department of Surgery, Johns Hopkins University, Baltimore, MD, USA
    Epigenetics 7:701-9. 2012
    ..92) and validation cohort (HR = 2.87). Our study demonstrates an efficient method to utilize functional methylation changes in BC for the development of effective biomarkers for detection and prognosis prediction of BC...
  18. doi request reprint Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker
    M Catherine Pietanza
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, New York, NY 10065, USA
    Clin Cancer Res 18:1138-45. 2012
    ..This phase II study was conducted to assess the efficacy of temozolomide in patients with relapsed small cell lung cancer (SCLC)...
  19. pmc Epigenetic therapy: use of agents targeting deacetylation and methylation in cancer management
    Allen S Ho
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Onco Targets Ther 6:223-32. 2013
    ..Here, we review recent progress in epigenetic treatments and consider their implications for future cancer therapy...